Details of the Drug-Related molecule(s) Interaction Atlas

US10081632, Compound 25 Drug Info

SCHEMBL19252896; BDBM286094; US10081632, Compound 25; Synthesis of (R) inverted question markN-(1-(4-aminobenzyl)-1H-pyrazol-4-yl)-9-methyl-6-oxo-6,7,8,9-tetrahydropyrido[3',2':4,5]pyrrolo[1,2-a]pyrazine-2-carboxamide hydrochloride salt

Cross-matching ID

PubChem CID

130338820

TTD Drug ID

DM3BDHN

General Information of Drug (ID: DM3BDHN)

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Patented Agent(s)

Preclinical Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Ribosomal protein S6 kinase alpha-6 (RSK6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CID 138805970	DMINXMY	N. A.	N. A.	Patented	[1]
BI-D1870	DMK3SAF	Chronic lymphocytic leukaemia	2A82.0	Preclinical	[2]
PMID22564207C25b	DMBMYKQ	Discovery agent	N.A.	Investigative	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Ribosomal protein S6 kinase alpha-6 (RSK6)	TT3KYWB	KS6A6_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Substituted tetrahydropyrido[3,2:4,5]pyrrolo[1,2-a]pyrazine-2-carboxamides as RSK inhibitors. US9771366.
2	BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo. Biochem J. 2007 Jan 1;401(1):29-38.
3	Discovery of an orally efficacious inhibitor of anaplastic lymphoma kinase. J Med Chem. 2012 May 24;55(10):4580-93.